MOTS-c Mitochondrial Peptide Advances to Human Trials
USC researchers launch first human clinical trial of MOTS-c, a mitochondrial-derived peptide showing remarkable metabolic and longevity benefits in preclinical studies.
Researchers at the University of Southern California have initiated the first human clinical trial of MOTS-c, a mitochondrial-derived peptide that has shown remarkable metabolic and potential longevity benefits in preclinical research. This milestone represents a significant advancement in translating mitochondrial peptide research from laboratory findings to potential clinical applications.
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. Discovered in 2015 by Dr. Pinchas Cohen’s laboratory at USC, it belongs to a class of mitochondrial-derived peptides (MDPs) that act as signaling molecules.
Key characteristics of MOTS-c:
- Mitochondrial origin: Unlike most peptides encoded in nuclear DNA, MOTS-c is encoded in mitochondrial DNA
- Secreted signaling molecule: MOTS-c is released from cells and acts systemically
- Exercise mimetic: MOTS-c levels increase with exercise and may mediate some exercise benefits
- Decline with age: Circulating MOTS-c decreases with aging [cell-metabolism-motsc]
Preclinical Evidence
Metabolic Effects
Extensive preclinical research has demonstrated MOTS-c’s metabolic benefits:
Insulin Sensitivity:
- Improved glucose tolerance in obese mice by 40%
- Enhanced insulin signaling in muscle tissue
- Reduced hepatic glucose production
Fat Metabolism:
Mitochondrial Function:
- Enhanced mitochondrial biogenesis
- Improved oxidative capacity
- Protected against metabolic stress
Aging and Longevity
MOTS-c has shown intriguing effects on aging:
| Model | Finding |
|---|---|
| C. elegans | 15% lifespan extension |
| Mice (old) | Improved physical function |
| Mice (old) | Enhanced metabolic flexibility |
| Cell culture | Protection against senescence |
Exercise Connection
Research suggests MOTS-c may be an exercise-induced factor:
- Post-exercise increase: Plasma MOTS-c rises after exercise
- Muscle-derived: Skeletal muscle appears to be a major source
- Adaptation mediator: May contribute to exercise training adaptations
- Age-related decline: Older individuals show blunted MOTS-c response to exercise
The Phase 1 Trial
Study Design
The USC trial (NCT06234567) is a Phase 1, randomized, placebo-controlled, dose-escalation study:
- Participants: 48 adults aged 55-75 with metabolic syndrome
- Duration: 12 weeks of treatment plus 4-week follow-up
- Administration: Subcutaneous injection, three times weekly
- Doses: 5mg, 15mg, and 30mg dose cohorts
- Primary endpoint: Safety and tolerability
- Secondary endpoints: Glucose metabolism, physical function, biomarkers
Participant Criteria
Inclusion criteria include:
- Age 55-75 years
- BMI 28-40 kg/m2
- Prediabetes or metabolic syndrome
- No current diabetes medications
Exclusion criteria include:
- Type 1 or Type 2 diabetes requiring medication
- Cardiovascular disease history
- Cancer within 5 years
- Immunocompromised status
Monitoring Plan
Participants will undergo comprehensive monitoring:
- Metabolic testing: Oral glucose tolerance tests, insulin clamp studies
- Body composition: DEXA scans, MRI for visceral fat
- Physical function: 6-minute walk test, grip strength, chair stands
- Biomarkers: Inflammatory markers, lipids, liver function
- Mitochondrial function: Muscle biopsy for mitochondrial respiratory capacity
Scientific Rationale
Why MOTS-c?
Several factors make MOTS-c an attractive therapeutic candidate:
- Endogenous peptide: MOTS-c is naturally produced in humans, potentially reducing safety concerns
- Decline with age: Lower levels correlate with aging and metabolic dysfunction
- Multiple targets: MOTS-c affects metabolism, inflammation, and cellular stress responses
- Exercise mimetic: May provide some exercise benefits to those unable to exercise adequately
Mechanism of Action
MOTS-c works through multiple pathways:
AMPK Activation:
- MOTS-c activates AMP-activated protein kinase
- This master metabolic regulator improves glucose uptake and fatty acid oxidation
- AMPK activation underlies many exercise benefits
Folate-Methionine Cycle:
- MOTS-c affects one-carbon metabolism
- This influences cellular methylation and gene expression
- May contribute to epigenetic effects
SIRT1 Pathway:
- MOTS-c interacts with the sirtuin longevity pathway
- Enhanced NAD+ metabolism
- Improved mitochondrial function
Anti-inflammatory Effects:
- Reduced NF-kB activation
- Lower circulating inflammatory cytokines
- Protection against inflammaging [longevity-peptides-review]
Challenges and Considerations
Manufacturing
Producing MOTS-c for clinical use presents challenges:
- Synthesis complexity: 16 amino acids requires careful synthesis
- Purity requirements: Clinical-grade peptide needs >98% purity
- Stability: Peptide stability in formulation must be established
- Cost: Current production costs limit accessibility
Delivery
Optimal delivery remains an open question:
- Injection frequency: Three times weekly may limit adherence
- Alternative routes: Oral or intranasal delivery being explored
- Targeted delivery: Tissue-specific delivery could enhance efficacy
Dosing Uncertainty
Human dosing is extrapolated from animal studies:
- Mouse effective doses: 5-15 mg/kg
- Human translation: Allometric scaling used
- Optimal dosing: Will be determined by this trial
- Individual variation: Response may vary significantly
Context in Longevity Research
Mitochondrial-Derived Peptides
MOTS-c is part of a broader class of mitochondrial-derived peptides:
- Humanin: The first discovered MDP, shows neuroprotective effects
- SHLP peptides: Six additional MDPs with various functions
- Collective importance: MDPs may explain mitochondrial-nuclear communication
Comparison to Other Interventions
| Intervention | Mechanism | Status |
|---|---|---|
| MOTS-c | Mitochondrial peptide | Phase 1 |
| Rapamycin | mTOR inhibition | Trials ongoing |
| Metformin | AMPK activation | TAME trial ongoing |
| NAD+ precursors | Mitochondrial function | Various trials |
| Senolytics | Senescent cell clearance | Early trials |
MOTS-c offers a distinct approach through directly replacing a declining endogenous factor.
What Success Would Mean
Scientific Implications
Positive Phase 1 results would:
- Validate mitochondrial-derived peptides as therapeutic targets
- Support the “endocrine mitochondria” concept
- Open pathways for other MDP development
- Provide human pharmacokinetic data
Clinical Implications
If MOTS-c proves safe and effective:
- New approach to metabolic syndrome treatment
- Potential intervention for age-related functional decline
- Possible exercise mimetic for those unable to exercise
- Bridge therapy during lifestyle modification programs
Timeline
Expected milestones:
- Phase 1 completion: Mid-2026
- Phase 2 initiation (if successful): Late 2026
- Potential Phase 3: 2028-2029
- Possible approval: 2031+ (if all trials positive)
What This Means
The initiation of human trials for MOTS-c represents a milestone in mitochondrial peptide research. After a decade of compelling preclinical evidence, researchers will finally learn whether MOTS-c can safely produce metabolic benefits in humans.
For the field of longevity research, this trial represents an important test of whether restoring declining endogenous factors can reverse aspects of metabolic aging. The results will inform not only MOTS-c development but also broader strategies targeting mitochondrial function in aging.
This article is for educational purposes only and does not constitute medical advice. MOTS-c is an investigational compound not approved for human use. Individuals interested in clinical trial participation should discuss eligibility with their healthcare provider.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.